CPI Pharmacology & Medication Management 3

Question 1

A blinded Phase III trial uses placebo control. The study drug is a capsule with a distinctive bitter taste. Participants frequently guess their assignment. This is an example of which methodological problem?

Accepted Answer

Unblinding due to pharmacological clues

Answer

Distinctive organoleptic properties such as taste or smell can unblind participants, compromising the integrity of blinding and introducing performance and reporting bias.

Question 2

A participant on warfarin enrolls in a trial of an azole antifungal. The azole inhibits CYP2C9. What is the expected pharmacodynamic consequence?

Accepted Answer

Increased anticoagulant effect and bleeding risk

Answer

CYP2C9 metabolizes the more potent S-warfarin; CYP2C9 inhibition raises warfarin levels, intensifying anticoagulation and increasing hemorrhage risk.

Question 3

An investigator is designing a First-in-Human (FIH) trial. The starting dose is calculated using the NOAEL from animal studies. The human equivalent dose (HED) is derived by:

Accepted Answer

Dividing the animal NOAEL by an allometric scaling factor based on body surface area

Answer

HED is calculated by dividing the animal NOAEL (in mg/kg) by a body surface area conversion factor (Km ratio), then applying a safety factor to determine the maximum recommended starting dose.

Question 4

In a trial, drug X has a narrow therapeutic index and is 95% protein-bound. A co-administered drug Y displaces X from albumin binding sites. What is the immediate pharmacokinetic effect?

Accepted Answer

Transient increase in free (unbound) drug X, rapidly corrected by increased clearance

Answer

Protein displacement briefly raises free drug levels, but the increased free fraction also increases clearance and distribution, usually returning unbound concentrations to near-baseline rapidly.

Question 5

A participant in an oncology trial develops grade 3 thrombocytopenia (platelets 25,000/µL). Per ICH E6 GCP guidelines, what is the investigator's primary obligation regarding this event?

Accepted Answer

Assess causality, treat the participant, and report as a serious adverse event to the sponsor

Answer

Grade 3 thrombocytopenia is serious; the investigator must ensure participant safety, assess causality, and report the SAE to the sponsor within required timeframes per ICH E6.

(CPI) Certified Physician Investigator Practice Test

(CPI) Certified Physician Investigator Practice Test

CPI Pharmacology & Medication Management 3